20 February 2024
Zu viele Resistenzen, aber kaum neue Antibiotika, – weil die Entwicklung zu wenig profitabel ist. Nun wurde zum ersten Mal die Studie und die Zulassung für ein neues Antibiotikum von einer öffentlich finanzierten Stiftung bezahlt
Receive updates on GARDP’s efforts to transform lives and counter antibiotic resistance around the world.
By ticking the box you confirm you agree to hearing from GARDP. We will use the information you provide with this form to email you updates on our work.
You can change your mind at any time by clicking the unsubscribe link in the footer of any email newsletter you receive from us, or by contacting us at contact@gardp.org. We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking Subscribe below, you agree that we may process your information in accordance with these terms. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing.Learn about Mailchimp legal policies
Notification
Your are leaving GARDP US to transition to the GARDP Global Website
Let’s go!
